Mineralys Therapeutics, Inc. (MLYS) Stock

Mineralys Therapeutics, Inc. (MLYS) is a Healthcare stock trading at $24.63 (as of 2026-06-18), with a market capitalization of $2.60B and a trailing P/E of -16.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hypertension and related cardiovascular conditions. Its lead candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor being studied for patients with uncontrolled or resistant hypertension.

Valuation — source: SEC EDGAR (first-party)
Price$24.63
Market Cap$2.60B
P/E Ratio-16.0
EV / EBITDA-14.5
Price / Book4.07
DCF Value (model)$-27.33
DCF Upside vs Price-211.0%
Profitability & Growth — source: SEC EDGAR
Return on Equity-23.8%
Current Ratio44.33
Valuation vs Sector & Industry
Stock P/E-16.0
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-176.3%
vs Industry-192.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCatalys Pacific, LLC ($214.11M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJon Congleton
Employees51
CountryUS
IPO Date2023-02-10

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • IDEAYA Biosciences, Inc. (IDYA)
  • Nuvation Bio Inc. (NUVB)
  • Disc Medicine, Inc. (IRON)
  • Arcus Biosciences, Inc. (RCUS)
  • Prestige Consumer Healthcare Inc. (PBH)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • Supernus Pharmaceuticals, Inc. (SUPN)
  • Beam Therapeutics Inc. (BEAM)
MLYS earnings history · MLYS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.